{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:45:00Z","timestamp":1787507100832,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001348","name":"Agency for Science Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ymthe.2024.06.037","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T18:38:34Z","timestamp":1719686314000},"page":"3504-3521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models"],"prefix":"10.1016","volume":"32","author":[{"given":"Lindsay","family":"Kua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Hoe","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee Ching","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheah Chen","family":"Seh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan D.","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar Wai","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3554-9527","authenticated-orcid":false,"given":"Lionel","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.06.037_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.06.037_bib2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.037_bib3","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.037_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.037_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2024.06.037_bib7","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and Design of Chimeric Antigen Receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.06.037_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2024.06.037_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3995","article-title":"Size-dependent activation of CAR-T cells","volume":"7","author":"Xiao","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3389\/fimmu.2020.01704","article-title":"A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes","volume":"11","author":"Schafer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib12","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.4049\/jimmunol.2000768","article-title":"Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells","volume":"206","author":"Okuno","year":"2021","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","article-title":"Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma","volume":"9","author":"Yi","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.06.037_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2024.06.037_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.06.037_bib16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/gt.2010.91","article-title":"Adoptive immunotherapy with genetically engineered T\u00a0cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response","volume":"17","author":"Hombach","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.037_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in\u00a0vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.06.037_bib18","first-page":"84","article-title":"Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease","volume":"50","author":"Engert","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.06.037_bib19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ijc.20098","article-title":"Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells","volume":"110","author":"Heuser","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.06.037_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044482","article-title":"An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T\u00a0cells for an anti-tumor attack","volume":"7","author":"Jahn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.06.037_bib21","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a Bispecific CD30\/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30(+) Malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.06.037_bib22","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.06.037_bib23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/protein\/gzh098","article-title":"Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in\u00a0vitro evolution approach","volume":"17","author":"Schlapschy","year":"2004","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ymthe.2024.06.037_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-4781(01)00235-4","article-title":"Structure of the Hodgkin's lymphoma-associated human CD30 gene and the influence of a microsatellite region on its expression in CD30(+) cell lines","volume":"1519","author":"D\u00fcrkop","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.06.037_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.06.037_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.611366","article-title":"Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T\u00a0cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.037_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T\u00a0cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.037_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T\u00a0cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib30","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2016.82","article-title":"Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack","volume":"24","author":"Hombach","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.037_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: Full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.06.037_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-020-00197-1","article-title":"Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T\u00a0cell therapy and associated strategies","volume":"8","author":"Nie","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ymthe.2024.06.037_bib34","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T\u00a0cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.037_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2024.06.037_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib37","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T\u00a0cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.06.037_bib38","doi-asserted-by":"crossref","first-page":"7946","DOI":"10.1073\/pnas.0502975102","article-title":"Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy","volume":"102","author":"Nagata","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.06.037_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jmr.605","article-title":"Human CD30: structural implications from epitope mapping and modeling studies","volume":"16","author":"Dong","year":"2003","journal-title":"J.\u00a0Mol. Recognit."},{"key":"10.1016\/j.ymthe.2024.06.037_bib40","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1089\/hum.2020.215","article-title":"Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains","volume":"32","author":"Choi","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.037_bib41","doi-asserted-by":"crossref","first-page":"12731","DOI":"10.1182\/blood-2022-157149","article-title":"Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial","volume":"140","author":"Brudno","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.037_bib42","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.037_bib43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T\u00a0cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.037_bib44","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41467-023-37616-4","article-title":"The IgG4 hinge with CD28 transmembrane domain improves V(H)H-based CAR T\u00a0cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.037_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23074056","article-title":"The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity","volume":"23","author":"Hirobe","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.06.037_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib47","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Kuppers","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.06.037_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.06.037_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex\u00a0vivo-engineered T\u00a0cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.037_bib50","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.V89.6.2042","article-title":"Treatment of refractory Hodgkin's disease with an anti-CD16\/CD30 bispecific antibody","volume":"89","author":"Hartmann","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.037_bib51","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ijc.2910550523","article-title":"A CD16\/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in\u00a0vitro and in\u00a0vivo","volume":"55","author":"Hombach","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2024.06.037_bib52","article-title":"Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin's Lymphoma Cells","volume":"9","author":"Guo","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2024.06.037_bib53","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.bbrc.2020.03.071","article-title":"Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties","volume":"527","author":"Fujiwara","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2024.06.037_bib54","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/1078-0432.CCR-17-0310","article-title":"(131)I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment","volume":"23","author":"D'Huyvetter","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.06.037_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/0126839-200809060-00004","article-title":"New approaches to prediction of immune responses to therapeutic proteins during preclinical development","volume":"9","author":"Perry","year":"2008","journal-title":"Drugs R. D."},{"key":"10.1016\/j.ymthe.2024.06.037_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318560-000000000-00000","article-title":"Prediction of immunogenicity of therapeutic proteins: validity of computational tools","volume":"24","author":"Bryson","year":"2010","journal-title":"BioDrugs"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:05:58Z","timestamp":1759611958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624004544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1525001624004544"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.037","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}